GeoVax Labs, Inc., a clinical-stage biotechnology company, announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026. The company's leadership will highlight 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026 during these premier investor forums.
The presentation will cover key clinical catalysts, regulatory milestones, and business development related to several programs. For CM04S1, the company's COVID-19 vaccine candidate, GeoVax will discuss clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations. The vaccine is currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients and as a booster in various patient populations.
In oncology, the company will present translational and clinical data supporting development of Gedeptin® for head and neck cancer and other high-value solid tumor indications. The novel oncolytic solid tumor gene-directed therapy recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
GeoVax will also discuss regulatory progress, clinical strategy, and potential registration pathways for GEO-MVA, its vaccine targeting Mpox and smallpox. Based on recent EMA regulatory guidance, the company anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials.
The presentation will include advancements in the company's manufacturing platform, focusing on continuous cell-line manufacturing enabling scalable, resilient, and domestic vaccine production. Business development opportunities to support pipeline advancement and long-term value creation will also be addressed.
David Dodd, Chairman and CEO of GeoVax Labs, will present on January 13, 2026, at 2:30 pm PST at the Hilton Union Square in San Francisco. The presentation will be webcast live and may be accessed through the Events & Presentations section of the company's website. Management will also host one-on-one investor and partner meetings throughout the conference to discuss GeoVax's progress across its diverse pipeline.
"We are pleased to share GeoVax's 2025 achievements with the global investor and biotech community at Biotech Showcase and the J.P. Morgan Healthcare Conference," said David Dodd. "Our team has delivered meaningful clinical and operational progress, strengthened our strategic position, and advanced multiple programs toward key inflection points in 2026."
The company's participation in these conferences is significant as it provides visibility into critical developments in vaccine technology and cancer therapies. GeoVax's focus on immunocompromised populations for COVID-19 vaccination addresses a persistent public health challenge, while its oncology and biodefense programs represent important advancements in their respective fields. The manufacturing platform developments could enhance vaccine production capabilities, potentially improving response to future health emergencies.
